Taysha Gene Therapies (TSHA) Operating Expenses (2020 - 2026)

Taysha Gene Therapies has disclosed Operating Expenses across 7 years of filings, most recently posting $43.5 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $43.5 million, up 83.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $140.0 million (up 46.21% YoY), and the FY2025 annual result was $120.3 million, up 20.52% from the prior year.
• Operating Expenses came in at $43.5 million for Q1 2026 at Taysha Gene Therapies, up from $33.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $56.5 million in Q4 2022 to a low of $19.8 million in Q4 2023.
• The 5-year median for Operating Expenses is $27.7 million (2024), against an average of $30.4 million.
• Across the five-year window, Operating Expenses slumped 64.85% in 2023 and soared 83.31% in 2026, its largest moves.
• Taysha Gene Therapies' Operating Expenses stood at $56.5 million in 2022, then plunged by 64.85% to $19.8 million in 2023, then advanced by 10.6% to $22.0 million in 2024, then soared by 53.89% to $33.8 million in 2025, then grew by 28.71% to $43.5 million in 2026.
• The last three Operating Expenses figures came in at $43.5 million (Q1 2026), $33.8 million (Q4 2025), and $34.0 million (Q3 2025), per Business Quant data.